San Diego-based Zogenix has updated its S-1, saying this morning the firm intends to offer 6 million shares of its common stock on the Nasdaq Global Market as ZGNX. The firm also said it currently estimates the firm's initial offering price at between $12.00 and $14.00 per share. Zogenix had filed for an IPO in September. The firm, which develops needle-free, delivery systems for the treatment of acute migraines and cluster headaches, is venture backed by Domain Associates, Clarus Lifesciences, Scale Venture Partners, Thomas McNerney & Partners, Chicago Growth Partners, Abingworth Bioventures, and others. The company's IPO is being underwritten by Wells Fargo Securities, Leerink Swann, Oppenheimer & Co., and Stifel Nicolaus Weisel.
Top NewsThursday, November 4, 2010
Zogenix Sets Pricing Range, Offering Size In IPO